ATORVASTATIN SANDOZ atorvastatin 10 mg film-coated tablet blister pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

atorvastatin calcium trihydrate, Quantity: 10.825 mg

Verfügbar ab:

Sandoz Pty Ltd

Darreichungsform:

Tablet, film coated

Zusammensetzung:

Excipient Ingredients: microcrystalline cellulose; croscarmellose sodium; hyprolose; lactose monohydrate; polysorbate 80; magnesium stearate; calcium carbonate; hypromellose; macrogol 6000; titanium dioxide

Verabreichungsweg:

Oral

Einheiten im Paket:

30

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Atorvastatin Sandoz is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. Prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemia, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated.,Atorvastatin Sandoz is indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD to reduce the risk of non-fatal myocardial infarction (MI) and non-fatal stroke.,These effects do not replace the need to independently control known causes of cardiovascular (CV) mortality and morbidity such as hypertension, diabetes and smoking

Produktbesonderheiten:

Visual Identification: White to off-white, round, biconvex film-coated tablets with A10 debossed on one side and plain on the other side; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 20 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure

Berechtigungsstatus:

Registered

Berechtigungsdatum:

2020-12-10